

<u>MA (EU) number</u>	<u>(Invented) name</u>	<u>Strength</u>	<u>Pharmaceutical Form</u>	<u>Route of Administration</u>	<u>Immediate Packaging</u>	<u>Content (concentration)</u>	<u>Pack size</u>
EU/1/20/1528/018	COMIRNATY Omicron XBB.1.5	--10	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)
EU/1/20/1528/019	COMIRNATY Omicron XBB.1.5	--10	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/020	COMIRNATY Omicron XBB.1.5	--10	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	195 multidose vials (1170 doses)
EU/1/20/1528/021	COMIRNATY Omicron XBB.1.5	--11	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	1.3 ml (10 doses)	10 multidose vials (100 doses)
EU/1/20/1528/022	COMIRNATY Omicron XBB.1.5	--12	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)
EU/1/20/1528/023	COMIRNATY Omicron XBB.1.5	--12	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/024	COMIRNATY Omicron XBB.1.5	--13	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	0.4 ml (10 doses)	10 multidose vials (100 doses)
EU/1/20/1528/025	COMIRNATY Omicron XBB.1.5	--10	Dispersion for injection	Intramuscular use	pre-filled syringe (cyclic-olefin copolymer)	0.432 ml (1 dose)	10 pre-filled syringes (10 doses)
EU/1/20/1528/026	COMIRNATY Omicron XBB.1.5	--14	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (3 doses)	10 multidose vials (30 doses)
EU/1/20/1528/027	COMIRNATY Omicron XBB.1.5	--10	Dispersion for injection	Intramuscular use	pre-filled syringe (glass)	0.418 ml (1 dose)	10 pre-filled syringes (10 doses)
EU/1/20/1528/028	COMIRNATY JN.1	--15	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)

EU/1/20/1528/029	COMIRNATY JN.1	--15	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/030	COMIRNATY JN.1	--15	Dispersion for injection	Intramuscular use	pre-filled syringe (glass)	0.418 ml (1 dose)	10 pre-filled syringes (10 doses)
EU/1/20/1528/031	COMIRNATY JN.1	--15	Dispersion for injection	Intramuscular use	pre-filled syringe (cyclic-olefin copolymer)	0.432 ml (1 dose)	10 pre-filled syringes (10 doses)
EU/1/20/1528/032	COMIRNATY JN.1	--16	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)
EU/1/20/1528/033	COMIRNATY JN.1	--16	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/034	COMIRNATY JN.1	--17	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	1.3 ml (10 doses)	10 multidose vials (100 doses)
EU/1/20/1528/035	COMIRNATY JN.1	--18	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (3 doses)	10 multidose vials (30 doses)
EU/1/20/1528/036	COMIRNATY JN.1	--19	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	0.4 ml (10 doses)	10 multidose vials (100 doses)
EU/1/20/1528/037	COMIRNATY KP.2	--20	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)
EU/1/20/1528/038	COMIRNATY KP.2	--20	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/039	COMIRNATY KP.2	--20	Dispersion for injection	Intramuscular use	pre-filled syringe (glass)	0.418 ml (1 dose)	10 pre-filled syringes (10 doses)
EU/1/20/1528/040	COMIRNATY KP.2	--21	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)

EU/1/20/1528/041	COMIRNATY KP.2	-- ²¹	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/042	COMIRNATY KP.2	-- ²²	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (3 doses)	10 multidose vials (30 doses)

--¹⁰: COMIRNATY Omicron XBB.1.5 30 micrograms/dose dispersion for injection (EU/1/20/1528/018-020, EU/1/20/1528/025, EU/1/20/1528/027):

1 dose (0.3 mL) contains 30 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Raxtozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5).

--¹¹: COMIRNATY Omicron XBB.1.5 10 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/021):

After dilution, 1 dose (0.2 mL) contains 10 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Raxtozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5).

--¹²: COMIRNATY Omicron XBB.1.5 10 micrograms/dose dispersion for injection (EU/1/20/1528/022-023):

1 dose (0.3 mL) contains 10 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Raxtozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5).

--¹³: COMIRNATY Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/024):

After dilution, 1 dose (0.2 mL) contains 3 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Raxtozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5).

--¹⁴: COMIRNATY Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/026):

After dilution, 1 dose (0.3 mL) contains 3 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Raxtozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5).

--¹⁵: COMIRNATY JN.1 30 micrograms/dose dispersion for injection (EU/1/20/1528/028-031):

1 dose (0.3 mL) contains 30 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

--16: COMIRNATY JN.1 10 micrograms/dose dispersion for injection (EU/1/20/1528/032-033):

1 dose (0.3 mL) contains 10 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

--17: COMIRNATY JN.1 10 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/034):

After dilution, 1 dose (0.2 mL) contains 10 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

--18: COMIRNATY JN.1 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/035):

After dilution, 1 dose (0.3 mL) contains 3 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

--19: COMIRNATY JN.1 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/036):

After dilution, 1 dose (0.2 mL) contains 3 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

--20: COMIRNATY KP.2 30 micrograms/dose dispersion for injection (EU/1/20/1528/037-039):

1 dose (0.3 mL) contains 30 micrograms mRNA encoding KP.2, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

The mRNA encoding KP.2 is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron KP.2).

--21: COMIRNATY KP.2 10 micrograms/dose dispersion for injection (EU/1/20/1528/040-041):

1 dose (0.3 mL) contains 10 micrograms mRNA encoding KP.2, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

The mRNA encoding KP.2 is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron KP.2).

--²²: COMIRNATY KP.2 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/042):

After dilution, 1 dose (0.3 mL) contains 3 micrograms mRNA encoding KP.2, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

The mRNA encoding KP.2 is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron KP.2).